Niraparib
| Clinical data | |
|---|---|
| Pronunciation | /nɪˈræpərɪb/ nih-RAP-uh-rib |
| Trade names | Zejula |
| Other names | MK-4827 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617007 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 73% |
| Protein binding | 83% |
| Metabolism | Carboxylesterases |
| Metabolites | M1 (carboxylic acid) |
| Elimination half-life | 36 hours |
| Excretion | 48% urine, 29% feces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.210.548 |
| Chemical and physical data | |
| Formula | C19H20N4O |
| Molar mass | 320.396 g·mol−1 |
| 3D model (JSmol) | |
| Solubility in water | 0.7–1.1 |
| |
| |
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.
Niraparib was approved for medical use in the United States and in the European Union in 2017.